For more than thirty years, bladder cancer has been treated with Bacillus Calmette–Guérin (BCG), the TLR2/TLR4 agonist that is the most effective TLR ligand in cancer therapy [40]. The gene discussed is TLR2; the disease is urinary bladder carcinoma.